Johnson & Johnson (JNJ) — Fair Value Analysis

Base-case fair value (P50): $218.67 · Current price: $263.04 · Verdict: Overvalued

The Verdict on JNJ

Johnson & Johnson (JNJ) currently trades at $263.04, a valuation that appears elevated when viewed through the lens of Monte Carlo simulations. Our analysis indicates a median fair value (P50) of $218.67, implying a potential -16.9% downside from its current trading level. This significant gap leads to a clear verdict: JNJ is overvalued based on our probabilistic models, suggesting the market is pricing in a premium not fully supported by underlying fundamentals in a simulated range of future scenarios.

How JNJ stacks up against Healthcare

Within the Healthcare sector, JNJ is assessed as an average quality tier company regarding its operational and financial health. While its market presence is undeniable, this "average" standing, when coupled with a stock price of $263.04 significantly above its $218.67 fair value, points to a valuation disconnect. The market seems to be applying a premium that outpaces JNJ's intrinsic value, even for a company of its scale within its sector. This valuation premium of -16.9% suggests that JNJ may be trading beyond what its fundamentals typically support compared to its peers within the average quality tier.

What this means for investors

For investors, the current overvalued verdict on JNJ, with an implied -16.9% gap from its median fair value of $218.67, suggests caution. The Monte Carlo simulations provide a probabilistic outlook, indicating that the prevailing $263.04 holds a notable premium. While a quality tier of "average" is respectable, it doesn't inherently justify the current valuation compared to its simulated fair value range. To gain a deeper understanding of the full bear and bull case distribution, along with the probability of upside scenarios, sign up for a free FairCurve account.